Literature DB >> 27186410

Podoplanin - a small glycoprotein with many faces.

Maciej Ugorski1, Piotr Dziegiel2, Jaroslaw Suchanski3.   

Abstract

Podoplanin is a small membrane glycoprotein with a large number of O-glycoside chains and therefore it belongs to mucin-type proteins. It can be found on the surface of many types of normal cells originating from various germ layers. It is present primarily on the endothelium of lymphatic vessels, type I pneumocytes and glomerular podocytes. Increased levels of podoplanin or its neo-expression have been found in numerous types of human carcinomas, but it is especially common in squamous cell carcinomas, such as cervical, larynx, oral cavity, skin and lung cancer. This small sialomucin is also seen on the surface of cancer-associated fibroblasts (CAFs) in lung adenocarcinomas, as well as in breast and pancreatic tumors. In most cancers, a high level of podoplanin expression, both in cancer cells, as well as in CAFs, is correlated with an increased incidence of metastasis to lymph nodes and shorter survival time of patients. Little is known about the biological role of podoplanin, however research carried out on mice with a knock-out gene of this glycoprotein shows that the presence of podoplanin determines normal development of lungs, the lymphatic system and heart. Podoplanin on cancer cells and CAFs seems to play an important role in the development and progression of various cancers. However, its role in these processes is both unclear and controversial. In this review, the role of podoplanin in both physiological processes and carcinogenesis is discussed.

Entities:  

Keywords:  Podoplanin; cancer marker; cancer-associated fibroblasts; carcinogenesis; physiological role

Year:  2016        PMID: 27186410      PMCID: PMC4859667     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  115 in total

Review 1.  Regulation of integrin-mediated cellular responses through assembly of a CAS/Crk scaffold.

Authors:  David Chodniewicz; Richard L Klemke
Journal:  Biochim Biophys Acta       Date:  2004-07-05

2.  Novel function for blood platelets and podoplanin in developmental separation of blood and lymphatic circulation.

Authors:  Pavel Uhrin; Jan Zaujec; Johannes M Breuss; Damla Olcaydu; Peter Chrenek; Hannes Stockinger; Elke Fuertbauer; Markus Moser; Paula Haiko; Reinhard Fässler; Kari Alitalo; Bernd R Binder; Dontscho Kerjaschki
Journal:  Blood       Date:  2010-01-28       Impact factor: 22.113

3.  Prognostic impact of cancer-associated stromal cells in patients with stage I lung adenocarcinoma.

Authors:  Masami Ito; Genichiro Ishii; Kanji Nagai; Ryo Maeda; Yasutaka Nakano; Atsushi Ochiai
Journal:  Chest       Date:  2012-07       Impact factor: 9.410

4.  D2-40, a novel monoclonal antibody against the M2A antigen as a marker to distinguish hemangioblastomas from renal cell carcinomas.

Authors:  Subhojit Roy; Albert Chu; John Q Trojanowski; Paul J Zhang
Journal:  Acta Neuropathol       Date:  2005-04-27       Impact factor: 17.088

5.  Isolation of a gene sequence induced later by tumor-promoting 12-O-tetradecanoylphorbol-13-acetate in mouse osteoblastic cells (MC3T3-E1) and expressed constitutively in ras-transformed cells.

Authors:  K Nose; H Saito; T Kuroki
Journal:  Cell Growth Differ       Date:  1990-11

6.  Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma.

Authors:  Kazuhiko Mishima; Yukinari Kato; Mika K Kaneko; Youya Nakazawa; Akiko Kunita; Naoya Fujita; Takashi Tsuruo; Ryo Nishikawa; Takanori Hirose; Masao Matsutani
Journal:  Acta Neuropathol       Date:  2006-05-05       Impact factor: 17.088

7.  Galectin-8 interacts with podoplanin and modulates lymphatic endothelial cell functions.

Authors:  Leah N Cueni; Michael Detmar
Journal:  Exp Cell Res       Date:  2009-03-04       Impact factor: 3.905

8.  The clinical significance of the tumor cell D2-40 immunoreactivity in non-small cell lung cancer.

Authors:  Kyuichi Kadota; Cheng-Long Huang; Dage Liu; Nariyasu Nakashima; Hiroyasu Yokomise; Masaki Ueno; Reiji Haba
Journal:  Lung Cancer       Date:  2010-01-12       Impact factor: 5.705

9.  Complementary DNA cloning and characterization of RANDAM-2, a type I membrane molecule specifically expressed on glutamatergic neuronal cells in the mouse cerebrum.

Authors:  Masaharu Kotani; Youichi Tajima; Taka Osanai; Atsushi Irie; Ken Iwatsuki; Masami Kanai-Azuma; Masato Imada; Hiroko Kato; Hiroshi Shitara; Hideo Kubo; Hitoshi Sakuraba
Journal:  J Neurosci Res       Date:  2003-09-01       Impact factor: 4.164

10.  Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas.

Authors:  Koji Shindo; Shinichi Aishima; Kenoki Ohuchida; Kenji Fujiwara; Minoru Fujino; Yusuke Mizuuchi; Masami Hattori; Kazuhiro Mizumoto; Masao Tanaka; Yoshinao Oda
Journal:  Mol Cancer       Date:  2013-12-20       Impact factor: 27.401

View more
  44 in total

1.  Lymphatics-associated genes are downregulated at transcription level in non-small cell lung cancer.

Authors:  Oksana Kowalczuk; Jerzy Laudanski; Wojciech Laudanski; Wieslawa Ewa Niklinska; Miroslaw Kozlowski; Jacek Niklinski
Journal:  Oncol Lett       Date:  2018-03-02       Impact factor: 2.967

2.  Intratumoral platelet aggregate formation in a murine preclinical glioma model depends on podoplanin expression on tumor cells.

Authors:  Barbara Costa; Tanja Eisemann; Jens Strelau; Ingrid Spaan; Andrey Korshunov; Hai-Kun Liu; Peter Bugert; Peter Angel; Heike Peterziel
Journal:  Blood Adv       Date:  2019-04-09

3.  Podoplanin expression is a prognostic biomarker but may be dispensable for the malignancy of glioblastoma.

Authors:  Tanja Eisemann; Barbara Costa; Patrick N Harter; Wolfgang Wick; Michel Mittelbronn; Peter Angel; Heike Peterziel
Journal:  Neuro Oncol       Date:  2019-02-19       Impact factor: 12.300

4.  Podoplanin neutralization improves cardiac remodeling and function after acute myocardial infarction.

Authors:  Maria Cimini; Venkata Naga Srikanth Garikipati; Claudio de Lucia; Zhongjian Cheng; Chunlin Wang; May M Truongcao; Anna Maria Lucchese; Rajika Roy; Cindy Benedict; David A Goukassian; Walter J Koch; Raj Kishore
Journal:  JCI Insight       Date:  2019-07-09

5.  Evaluation of Podoplanin Expression in Hepatocellular Carcinoma Using RNAscope and Immunohistochemistry - A Preliminary Report.

Authors:  Andreea Cioca; Anca Maria Cimpean; Raluca Amalia Ceausu; Valeria Tarlui; Alina Toma; Irina Marin; Marius Raica
Journal:  Cancer Genomics Proteomics       Date:  2017 Sep-Oct       Impact factor: 4.069

6.  Prognostic Value of Podoplanin in Various Tumors.

Authors:  Xiaohang Wang; Xueying Wang; Vladmir Carvalho; Qianqian Wang; Tingting Li; Jinbang Wang; Yang Chen; Chengming Ni; Subo Liu; Jiaxin Zhang
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

7.  Expression of Podoplanin in Mammary Cancers in Female Dogs.

Authors:  Paulina Borecka; Rafal Ciaputa; Izabela Janus; Aleksandra Piotrowska; Katarzyna Ratajczak-Wielgomas; Alicja Kmiecik; Marzena Podhorska-Okolów; Piotr Dzięgiel; Marcin Nowak
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

8.  Podoplanin expression in cancer-associated fibroblasts predicts unfavorable prognosis in node-negative breast cancer patients with hormone receptor-positive/HER2 - negative subtype.

Authors:  Yuko Tanaka; Takashi Ohno; Taichi Kadonaga; Yoshiteru Kidokoro; Makoto Wakahara; Kanae Nosaka; Tomohiko Sakabe; Yoshimasa Suzuki; Hiroshige Nakamura; Yoshihisa Umekita
Journal:  Breast Cancer       Date:  2021-01-22       Impact factor: 4.239

9.  Deficiency of the adrenomedullin-RAMP3 system suppresses metastasis through the modification of cancer-associated fibroblasts.

Authors:  Kun Dai; Megumu Tanaka; Akiko Kamiyoshi; Takayuki Sakurai; Yuka Ichikawa-Shindo; Hisaka Kawate; Nanqi Cui; Yangxuan Wei; Masaaki Tanaka; Shinji Kakihara; Shuhei Matsui; Takayuki Shindo
Journal:  Oncogene       Date:  2019-11-21       Impact factor: 9.867

10.  Myxoinflammatory fibroblastic sarcoma: an immunohistochemical and molecular genetic study of 73 cases.

Authors:  David Suster; Michael Michal; Huiya Huang; Shira Ronen; Stephanie Springborn; Maria Debiec-Rychter; Steven D Billings; John R Goldblum; Brian P Rubin; Michal Michal; Saul Suster; A Craig Mackinnon
Journal:  Mod Pathol       Date:  2020-06-08       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.